Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients

TORONTO, April 16, 2021 /CNW/ - On April 8, 2021, Eli Lilly and Company and Incyte announced the results of COV-BARRIER, a Phase 3 study evaluating baricitinib 4mg once daily plus standard of care (SoC) versus placebo plus SoC. The trial did not meet statistical significance on the primary endpoint, which was defined as a difference in the proportion of participants progressing to the first occurrence of non-invasive ventilation including high flow oxygen or invasive mechanical ventilation including extracorporeal membrane oxygenation (ECMO) or death by Day 28. Baricitinib-treated patients were 2.7 per cent less likely than those receiving standard of care to progress to ventilation (non-invasive or mechanical) or death, a difference that was not statistically significant (odds ratio [OR]: 0.85; 95% CI 0.67, 1.08; p=0.1800).

NewsGuest UserApril 16, 2021Lilly, Incyte, results, Phase 3 study, COV-BARRIER, baricitinib, COVID-19